The purpose of this clinical trial is to determine the safety and efficacy when an investigational medicine is given for a second time to participants with multiple myeloma. This study will also compare the safety and efficacy of the investigational medicine combined with carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.